 Catalyst Pharmaceuticals Inc NASDAQ: CPRX has received a favorable decision from the 11th Circuit Court of Appeals in its appeal to overturn a District Court decision upholding the FDA approval of another amifampridine product, Ruzurgi, despite existing Orphan Drug exclusivity for Catalysts Firdapse amifampridine. Amifampridine products are indicated for Lambert-Eaton myasthenic syndrome LEMS, a rare autoimmune disorder that affects the connection between nerves and muscles. 